Vivos Therapeutics (NASDAQ:VVOS) Posts Earnings Results, Misses Estimates By $0.07 EPS

Vivos Therapeutics (NASDAQ:VVOS) posted its quarterly earnings results on Wednesday. The company reported ($0.52) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.07), Zacks reports. Vivos Therapeutics had a negative net margin of 121.37% and a negative return on equity of 849.22%.

Vivos Therapeutics Trading Up 0.8%

Shares of Vivos Therapeutics stock traded up $0.00 during trading hours on Wednesday, hitting $0.59. The company’s stock had a trading volume of 275,390 shares, compared to its average volume of 191,576. Vivos Therapeutics has a 12 month low of $0.57 and a 12 month high of $7.95. The stock has a 50 day moving average of $1.06 and a 200 day moving average of $1.65. The company has a market capitalization of $8.09 million, a PE ratio of -0.29 and a beta of 6.25. The company has a debt-to-equity ratio of 3.31, a current ratio of 0.24 and a quick ratio of 0.24.

Insider Activity

In other Vivos Therapeutics news, major shareholder Michael C. Skaff purchased 1,353,625 shares of the stock in a transaction on Tuesday, March 31st. The stock was bought at an average cost of $1.34 per share, for a total transaction of $1,813,857.50. Following the completion of the acquisition, the insider directly owned 1,353,625 shares of the company’s stock, valued at $1,813,857.50. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 2.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. DRW Securities LLC lifted its stake in Vivos Therapeutics by 179.5% in the fourth quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after buying an additional 74,441 shares in the last quarter. Connective Capital Management LLC bought a new position in Vivos Therapeutics in the third quarter valued at approximately $620,000. B. Riley Wealth Advisors Inc. bought a new position in Vivos Therapeutics in the second quarter valued at approximately $220,000. Finally, XTX Topco Ltd bought a new position in Vivos Therapeutics in the second quarter valued at approximately $65,000. Institutional investors own 26.35% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on VVOS. Ascendiant Capital Markets cut their price target on Vivos Therapeutics from $5.50 to $3.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. HC Wainwright reduced their price objective on shares of Vivos Therapeutics from $7.00 to $2.50 and set a “buy” rating on the stock in a research note on Friday, April 17th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Vivos Therapeutics has an average rating of “Hold” and a consensus price target of $2.75.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.